Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

BACKGROUND: The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented. METHODS: Remission and resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Hibi, Toshifumi, Nakamura, Shiro, Lazar, Andreas, Robinson, Anne Martin, Skup, Martha, Mostafa, Nael Mohamed, Huang, Bidan, Thakkar, Roopal, Watanabe, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569655/
https://www.ncbi.nlm.nih.gov/pubmed/28321512
http://dx.doi.org/10.1007/s00535-017-1325-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569655/
https://www.ncbi.nlm.nih.gov/pubmed/28321512
http://dx.doi.org/10.1007/s00535-017-1325-2

Ejemplares similares